Current Report Filing (8-k)
May 05 2020 - 5:20PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
April
29, 2020
Date
of Report (Date of earliest event reported)
Immune
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Florida
|
|
000-54933
|
|
59-3226705
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.
|
2431
Aloma Ave, Suite 124, Winter Park, FL
|
|
32792
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code 888-613-8802
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of Exchange on which registered
|
Common
stock
|
|
IMUN
|
|
OTC
Markets
|
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
On
April 29, 2020, Mr. Michael K. Handley, director, president and CEO of Immune Therapeutics, Inc. (“Immune” or the
“Company”) tendered his resignation in a letter to the Company’s Board, which was formally accepted on April
30, 2020. Mr. Handley will remain in the leadership of the Company’s non-public affiliates, Cytocom, Inc. and Forte Biotechnology
Intl. Corp. The Immune Board appointed director Kevin J. Phelps as interim president and CEO. Concurrently, a mutual release and
non-disparagement agreement was executed between Mr. Handley and the Company. While amicable, the resignation was due to disagreements
between Mr. Handley and the Board on strategic direction and related milestones. The Board has assembled an experienced management
transition team to formulate and execute a strategy for long term viability of the Company to benefit its shareholders.
Director
Clifford A. Selsky MD PhD has been unable to participate in recent Board meetings and anticipates this to continue during the
current corporate and leadership transition, due to the demands of his pediatric medical practice during the COVID-19 pandemic.
Dr. Selsky therefore submitted his resignation to the Board on May 4, 2020. The Board thanked him for his years of valuable service
to the shareholders of the Company.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits. The following exhibits are filed herewith.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUNE
THERAPEUTICS, INC.
|
|
|
Date:
May 5, 2020
|
By:
|
/s/
Roscoe M. Moore
|
|
|
Roscoe
M. Moore Jr., Chairman
|
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jul 2023 to Jul 2024